Methylome Study in Sporadic Limb Malformations

NCT ID: NCT05555225

Last Updated: 2024-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-04-30

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Some limb malformations are known to be sporadic (non hereditary). For these malformations, no molecular cause was identified, even after whole genome sequencing. Methylation of CpG islands is an epigenetic process which is usually not transmitted to the descents. We hypothesize that sporadic limb malformations may be due to a methylation anomaly. This study will include patients with Amelia or Femur Fibula Ulna Syndrome. With patients consent, we will study the methylome on DNA samples already available in our laboratory. Each patient sample will be paired to a control of same tissue, age and sex. By bioinformatics comparison, we will identify differentially methylated candidate regions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amelia Femur Fibula Ulna Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with amelia

Patients with severe hypoplasia or agenesia of at least two limbs who gave their consent for the research and for whom a DNA sample is available in our laboratory

Methylome

Intervention Type OTHER

Epigenetic study : analysis of DNA methylation

Patients with Femur-Fibula-Ulna Syndrome

Patients with anomaly of at least one femur, one fibula and with oligodactyly who gave their consent for the research and for whom a DNA sample is available in our laboratory.

Methylome

Intervention Type OTHER

Epigenetic study : analysis of DNA methylation

Healthy subjects

Healthy subjects used as controls, who gave their consent for the research and for whom a DNA sample is available in our laboratory.

Methylome

Intervention Type OTHER

Epigenetic study : analysis of DNA methylation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Methylome

Epigenetic study : analysis of DNA methylation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Specific consent for this study
* DNA available in the laboratory
* For amelia : agenesia of 2 or 4 limbs
* For Femur-Fibula-Ulna Syndrome : hypoplasia or agenesia of the femur uni or bilateral with hypoplasia or agenesia or bowing of the fibula and/or of the ulna

Exclusion Criteria

* No consent
* No available DNA or poor quality of the DNA sample
* Patient under tutorship
* Pregnancy or nursing mother
* Patient non covered by the French social security
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Groupement Interrégional de Recherche Clinique et d'Innovation

OTHER

Sponsor Role collaborator

University Hospital, Lille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Perrine BRUNELLE, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Lille

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Perrine BRUNELLE, MD

Role: CONTACT

0320445962

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-A01441-42

Identifier Type: OTHER

Identifier Source: secondary_id

2021_0524

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Omics Gaucher Study: Multiomic Approach
NCT05526664 ACTIVE_NOT_RECRUITING